PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Research focused on the <strong>PharmaPoint</strong>: <strong>Peripheral</strong> <strong>Artery</strong> <strong>Disease</strong> <strong>Global</strong><br />
<strong>Drug</strong> <strong>Forecast</strong> <strong>and</strong> <strong>Market</strong> <strong>Analysis</strong> <strong>to</strong> <strong>2024</strong><br />
"The Report <strong>PharmaPoint</strong>: <strong>Peripheral</strong> <strong>Artery</strong> <strong>Disease</strong> <strong>Global</strong> <strong>Drug</strong> <strong>Forecast</strong> <strong>and</strong><br />
<strong>Market</strong> <strong>Analysis</strong> <strong>to</strong> <strong>2024</strong> provides information on pricing, market analysis, shares,<br />
forecast, <strong>and</strong> company profiles for key industry participants. <br />
<strong>Market</strong>ResearchReports.biz"<br />
In the 2014 base year, the global PAD market was worth approximately $543.4m, including<br />
both br<strong>and</strong>ed <strong>and</strong> generic drugs. By <strong>2024</strong>, <strong>Global</strong>Data expects that the global PAD market<br />
will experience significant expansion, with a Compound Annual Growth Rate (CAGR) of<br />
approximately 4.15%, equating <strong>to</strong> around $816.3m. The dramatic increase in the value of<br />
the overall global PAD therapeutics market will be partly attributable <strong>to</strong> the launch of<br />
several PAD drugs currently in latestage pipeline development, which <strong>Global</strong>Data believes<br />
have extraordinary potential. These include the novel antithrombotic pharmacological<br />
agents, Merck & Co.s Zontivity (vorapaxar), AstraZenecas Brilinta (ticagrelor), <strong>and</strong> Bayer<br />
<strong>and</strong> Janssens (a subsidiary of Johnson & Johnson) Xarel<strong>to</strong> (rivaroxaban), which have the<br />
capacity <strong>to</strong> reform the antiplatelet <strong>and</strong> anticoagula<strong>to</strong>ry PAD treatment l<strong>and</strong>scape.<br />
<strong>Global</strong>Data believes that the size of the market for pharmacological agents designed <strong>to</strong><br />
alleviate PAD symp<strong>to</strong>ms, including cilostazol, naftidrofuryl, <strong>and</strong> pen<strong>to</strong>xifylline, will<br />
diminish throughout the forecast period. <strong>Global</strong>Data accredits this diminishing <strong>to</strong> three<br />
fac<strong>to</strong>rs: first, the advent of advanced revascularization procedures, as characterized by<br />
gradual, incremental improvements in success rates over time; second, the fact that current<br />
drug treatments, such as the ones mentioned above, display lackluster efficacy, perturbing<br />
safety attributes, <strong>and</strong> inconvenient dosing regimens; <strong>and</strong> third, the lack of novel, superior,<br />
premiumpriced, drug therapies in the late stages of the PAD pipeline that could encroach<br />
on the patient shares of existing, rival pharmacological treatments.<br />
The overall level of unmet need in the PAD market is high, resulting in a generous amount<br />
of room for new entrants <strong>to</strong> capitalize on. With respect <strong>to</strong> the first three traditional pillars<br />
of PAD treatment antithrombotic pharmacological agents, lipidlowering medical<br />
therapies, <strong>and</strong> antihypertensive drugs the level of unmet need will fall once the current<br />
crop of latephase PAD therapies portrayed in this report arrives on<strong>to</strong> the market. With<br />
respect <strong>to</strong> drugs that allay the symp<strong>to</strong>ms of PAD, the level of unmet need here is<br />
astronomical. Present medical treatments are limited, archaic, <strong>and</strong> some have restricted<br />
availability.<br />
View Report At :http://www.marketresearchreports.biz/analysis/511689
Highlights<br />
Key Questions Answered<br />
From a clinical st<strong>and</strong>point, there is a dem<strong>and</strong> for novel medical therapies that target <strong>and</strong><br />
relieve the symp<strong>to</strong>ms of PAD in IC <strong>and</strong> CLI patients. KOLs interviewed by <strong>Global</strong>Data<br />
expressed a desire for secondgeneration drug treatments that display superior efficacy <strong>and</strong><br />
favorable safety profiles compared <strong>to</strong> existing pharmacological. Environmental unmet needs<br />
for this particular indication include physician education, patient awareness, greater<br />
screening, <strong>and</strong> improved guidelines. What other unmet needs exist in this market? Will the<br />
drugs under development fulfil the unmet needs of the PAD market?<br />
The current latestage PAD pipeline encompasses AstraZenecas Brillinta, Bayer/Janssens<br />
Xarel<strong>to</strong> <strong>and</strong> Mercks Zontivity. Will the latestage drugs make a significant impact on the<br />
PAD market? Which of these drugs will have the highest peak sales at the highest CAGR,<br />
<strong>and</strong> why?<br />
Key Findings<br />
The major drivers of this expansion in the PAD market will be the advent of novel<br />
antithrombotic agents, such as Brilinta <strong>and</strong> Xarel<strong>to</strong>, on<strong>to</strong> the PAD stage, <strong>and</strong> the increasing<br />
prevalence of PAD across all of the 8MM.<br />
The major global barrier <strong>to</strong> growth in the PAD market will be the losses of patent<br />
protection <strong>and</strong> market exclusivity on marketed <strong>and</strong> key pipeline drugs during the forecast<br />
period, such as AstraZenecas Cres<strong>to</strong>r (rosuvastatin), Sanofis Plavix (clopidogrel), Brilinta,<br />
<strong>and</strong> Xarel<strong>to</strong>.<br />
The overall level of unmet need in the PAD market is high, resulting in a generous amount<br />
of room for new entrants <strong>to</strong> capitalize on. <strong>Global</strong>Data forecasts that once Brilinta <strong>and</strong><br />
Xarel<strong>to</strong>, pipeline pharmacological agents currently in latestage clinical trials for PAD,<br />
navigate their way through the regula<strong>to</strong>ry l<strong>and</strong>scape <strong>and</strong> secure approval for the PAD<br />
indication, they will address some of the unmet needs in this area.<br />
Download Sample copy of this Report at:<br />
http://www.marketresearchreports.biz/sample/sample/511689<br />
Scope<br />
Overview of peripheral artery disease (PAD), including epidemiology, etiology,<br />
pathophysiology, symp<strong>to</strong>ms, diagnosis, <strong>and</strong> treatment guidelines.<br />
Annualized PAD therapeutics market revenue, annual cost of therapy <strong>and</strong> treatment usage<br />
pattern data from 2014 <strong>and</strong> forecast for ten years <strong>to</strong> <strong>2024</strong>.<br />
Key <strong>to</strong>pics covered include strategic competi<strong>to</strong>r assessment, market characterization,<br />
unmet needs, clinical trial mapping <strong>and</strong> implications for the PAD therapeutics market.<br />
Pipeline analysis: comprehensive data split across different phases, emerging novel trends<br />
under development, <strong>and</strong> detailed analysis of latestage pipeline drugs.<br />
<strong>Analysis</strong> of the current <strong>and</strong> future market competition in the global PAD therapeutics<br />
market. Insightful review of the key industry drivers, restraints <strong>and</strong> challenges. Each trend<br />
is independently researched <strong>to</strong> provide qualitative analysis of its implications.<br />
Reasons <strong>to</strong> buy
The report will enable you <strong>to</strong> <br />
Develop <strong>and</strong> design your inlicensing <strong>and</strong> outlicensing strategies through a review of<br />
pipeline products <strong>and</strong> technologies, <strong>and</strong> by identifying the companies with the most robust<br />
pipeline. Additionally a list of acquisition targets included in the pipeline product company<br />
list.<br />
Develop business strategies by underst<strong>and</strong>ing the trends shaping <strong>and</strong> driving the global<br />
PAD therapeutics market.<br />
Drive revenues by underst<strong>and</strong>ing the key trends, innovative products <strong>and</strong> technologies,<br />
market segments, <strong>and</strong> companies likely <strong>to</strong> impact the global PAD therapeutics market in<br />
future.<br />
Formulate effective sales <strong>and</strong> marketing strategies by underst<strong>and</strong>ing the competitive<br />
l<strong>and</strong>scape <strong>and</strong> by analysing the performance of various competi<strong>to</strong>rs.<br />
Identify emerging players with potentially strong product portfolios <strong>and</strong> create effective<br />
counterstrategies <strong>to</strong> gain a competitive advantage.<br />
Track drug sales in the global PAD therapeutics market from 2014<strong>2024</strong>.<br />
Organize your sales <strong>and</strong> marketing efforts by identifying the market categories <strong>and</strong><br />
segments that present maximum opportunities for consolidations, investments <strong>and</strong> strategic<br />
partnerships.<br />
Table Of Content<br />
1 Table of Contents 12<br />
1.1 List of Tables 18<br />
1.2 List of Figures 22<br />
2 Introduction 25<br />
2.1 Catalyst 25<br />
2.2 Related Reports 26<br />
2.3 Upcoming Related Reports 26<br />
3 <strong>Disease</strong> Overview 27<br />
3.1 Etiology <strong>and</strong> Pathophysiology 28<br />
3.1.1 Etiology 28<br />
3.1.2 Pathophysiology 30<br />
3.2 Classification <strong>and</strong> Staging Systems 31<br />
3.3 Symp<strong>to</strong>ms <strong>and</strong> Clinical Presentation 33<br />
3.4 Prognosis 37<br />
3.5 Quality of Life 41<br />
4 Epidemiology 43<br />
4.1 <strong>Disease</strong> Background 43<br />
4.2 Risk Fac<strong>to</strong>rs <strong>and</strong> Comorbidities 44<br />
4.3 <strong>Global</strong> Trends 46<br />
4.4 <strong>Forecast</strong> Methodology 47<br />
4.4.1 Sources Used 48<br />
4.4.2 Sources Not Used 61<br />
4.4.3 <strong>Forecast</strong> Assumptions <strong>and</strong> Methods 61<br />
4.5 Epidemiological <strong>Forecast</strong> of Total Prevalent Cases of PAD (2014<strong>2024</strong>) 67<br />
4.5.1 Total Prevalent Cases of PAD 67<br />
4.5.2 AgeSpecific Total Prevalent Cases of PAD 68<br />
4.5.3 SexSpecific Total Prevalent Cases of PAD 70<br />
4.5.4 AgeAdjusted Total Prevalence of PAD 72
4.5.5 Total Prevalent Asymp<strong>to</strong>matic <strong>and</strong> Symp<strong>to</strong>matic Cases of PAD 73<br />
4.5.6 Total Prevalent Cases of PAD with Intermittent Claudication <strong>and</strong> PAD with Critical<br />
Limb Ischemia 75<br />
4.5.7 Proportion of Total PAD Cases that Present as Asymp<strong>to</strong>matic, PAD with Intermittent<br />
Claudication, <strong>and</strong> PAD with Critical Limb Ischemia 77<br />
4.5.8 Total Prevalent Cases of PAD with Hypertension <strong>and</strong> PAD with Diabetes 78<br />
4.6 Epidemiological <strong>Forecast</strong> of Diagnosed Prevalent Cases of PAD (2014<strong>2024</strong>) 80<br />
4.6.1 Diagnosed Prevalent Cases of PAD 80<br />
4.6.2 AgeSpecific Diagnosed Prevalent Cases of PAD 82<br />
4.6.3 SexSpecific Diagnosed Prevalent Cases of PAD 84<br />
4.6.4 Diagnosed Prevalent Asymp<strong>to</strong>matic <strong>and</strong> Symp<strong>to</strong>matic Cases of PAD 86<br />
4.6.5 Diagnosed Prevalent Cases of PAD with Intermittent Claudication <strong>and</strong> PAD with<br />
Critical Limb Ischemia 88<br />
4.6.6 Proportion of Diagnosed PAD Cases that Present as Symp<strong>to</strong>matic, PAD with<br />
Intermittent Claudication, <strong>and</strong> PAD with Critical Limb Ischemia 90<br />
4.6.7 Diagnosed Prevalent Cases of PAD with Hypertension <strong>and</strong> PAD Cases with Diabetes<br />
91<br />
Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreportsbiz<br />
About us<br />
<strong>Market</strong>ResearchReports.biz is the most comprehensive collection of market research<br />
reports. <strong>Market</strong>ResearchReports.Biz services are specially designed <strong>to</strong> save time <strong>and</strong> money<br />
for our clients. We are a one s<strong>to</strong>p solution for all your research needs, our main offerings<br />
are syndicated research reports, cus<strong>to</strong>m research, subscription access <strong>and</strong> consulting<br />
services. We serve all sizes <strong>and</strong> types of companies spanning across various industries.<br />
Contact<br />
Mr. Nachiket<br />
State Tower<br />
90 Sate Street, Suite 700<br />
Albany, NY 12207<br />
Tel: +15186212074<br />
Website: http://www.marketresearchreports.biz/<br />
E: sales@marketresearchreports.biz